Eli Lilly presents exploratory biomarker data from TOGETHER‑PsO Phase 3b trial
Eli Lilly disclosed new exploratory results from its TOGETHER‑PsO Phase 3b study, which evaluated Taltz (ixekizumab) together with Zepbound (tirzepatide) versus Taltz alone in adults with moderate‑to‑severe plaque psoriasis and obesity or overweight. The trial enrolled 274 participants who were randomized 1:1 and followed for 52 weeks. By Week 12 the combination showed broader biomarker changes, and by Week 36 it altered 482 proteins and 467 genes compared with 140 proteins and 16 genes for Taltz alone, indicating greater reductions in inflammatory activity. The data were presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas.
Why it matters
The biomarker findings suggest a mechanistic link between immune and metabolic pathways, which could support a combined therapeutic approach for patients with both psoriasis and obesity. Investors may view the broader biological activity as a potential differentiator for Lilly’s portfolio, though no efficacy or commercial impact is quantified in the release.
Key facts
- 1The TOGETHER‑PsO trial is a 52‑week Phase 3b study that enrolled 274 participants. prnewswire.com
- 2Participants were randomized 1:1 to receive Taltz alone or Taltz plus Zepbound. prnewswire.com
- 3At Week 12 the combination therapy showed broader biomarker responses than Taltz alone. prnewswire.com
- 4By Week 36 the combination altered 482 differentially expressed proteins versus 140 with Taltz alone. prnewswire.com
- 5By Week 36 the combination altered 467 differentially expressed genes versus 16 with Taltz alone. prnewswire.com
- 6The primary endpoint assesses the proportion of participants achieving PASI 100 and ≥10% weight reduction at Week 36. investor.lilly.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.